SCHEDULE: Vanguard Discloses 5.28% Stake in Amylyx Pharmaceuticals

The Vanguard Group has reported a 5.28% beneficial ownership stake in Amylyx Pharmaceuticals Inc., holding 5,804,912 shares of common stock.

Summary

• The Vanguard Group, an investment adviser, filed a Schedule 13G indicating beneficial ownership of 5,804,912 shares of Common Stock in Amylyx Pharmaceuticals Inc.
• This ownership represents 5.28% of the total class of securities.
• Vanguard holds shared voting power over 698,623 shares and shared dispositive power over all 5,804,912 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• An internal realignment at The Vanguard Group, Inc. on January 12, 2026, means it no longer performs portfolio management or administers proxy voting, with subsidiaries expected to report beneficial ownership separately in the future.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant stake by a major institutional investor like Vanguard can imply a degree of confidence and stability, though it is a passive investment.

Positives

• A significant stake by a major institutional investor like The Vanguard Group can signal confidence in the company's long-term prospects.
• Vanguard's investment is for ordinary course of business, not for control, suggesting a passive, long-term investment strategy.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional ownership by major asset managers like The Vanguard Group is a common occurrence for publicly traded companies, especially those in the biotechnology and pharmaceutical sectors which often attract long-term growth investors. This filing indicates that Amylyx Pharmaceuticals has reached a level of market capitalization and liquidity to be included in broad market index funds and actively managed portfolios.

Stakeholder Impact

• Shareholders: Increased institutional ownership can enhance liquidity and potentially reduce volatility. It also signals that a major fund manager sees value in the company.
• Management: The presence of a significant passive institutional investor like Vanguard typically encourages adherence to good corporate governance practices, though Vanguard explicitly states its investment is not for control purposes.

Next Steps

• The Vanguard Group's subsidiaries or business divisions are anticipated to report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on SEC Release No. 34-39538, following an internal realignment on January 12, 2026.

Key Dates

Keywords

Amylyx Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Investment Adviser, AMLYX, Pharmaceuticals